Clinical Trial Update: Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Early phase trial update evaluating regorafenib combined with a PD-1 inhibitor for colorectal cancer; current status is unknown with Phase 1/2 design.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Colorectal Cancer, Immunotherapy | Phase 1, Phase 2 | Status: UNKNOWN